Safety and pharmacokinetics of BAY 1817080, a P2X3 receptor antagonist, in healthy subjects: Results from a double-blind, randomised study

被引：0
|
作者：
Friedrich, Christian [1 ]
Francke, Klaus [1 ]
Gashaw, Isabella [1 ]
Scheerans, Christian [1 ]
Klein, Stefan [1 ]
Fels, Lueder [1 ]
Smith, Jaclyn [2 ,3 ]
Hummel, Thomas [4 ]
Morice, Alyn [5 ]
机构：
[1] Bayer AG, Leverkusen, Germany
[2] Univ Manchester, Immun & Resp Med, Manchester, Lancs, England
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[4] Tech Univ Dresden, Dept Otorhinolaryngol, Smell & Taste Clin, Dresden, Germany
[5] Univ Hull, Resp Res Grp, Hull York Med Sch, Kingston Upon Hull, N Humberside, England
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2021年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P132
引用
收藏
页码：1614 / 1616
页数：3
相关论文
共 50 条
  • [31] A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough
    Lorcan McGarvey
    Jaclyn A. Smith
    Alyn Morice
    Surinder S. Birring
    Kian Fan Chung
    Peter V. Dicpinigaitis
    Akio Niimi
    Michael S. Benninger
    Mandel Sher
    Yuko Matsunaga
    Sayaka Miyazaki
    Mitsuaki Machida
    Hiroyuki Ishihara
    Adnan Mahmood
    Juan-Carlos Gomez
    Lung, 2023, 201 : 25 - 35
  • [32] A randomised, double-blind, ascending multiple-dose study with ponesimod, a selective S1P1 receptor modulator: safety, pharmacokinetics, pharmacodynamics
    Brossard, P.
    Maatouk, H.
    Halabi, A.
    Cavallaro, M.
    Dingemanse, J.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 423 - 423
  • [33] Effect of Telavancin on the Pharmacokinetics of the Cytochrome P450 3A Probe Substrate Midazolam: A Randomized, Double-Blind, Crossover Study in Healthy Subjects
    Wong, Shekman L.
    Goldberg, Michael R.
    Ballow, Charles H.
    Kitt, Michael M.
    Barriere, Steven L.
    PHARMACOTHERAPY, 2010, 30 (02): : 136 - 143
  • [34] The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study
    Morice, Alyn H.
    Kitt, Michael M.
    Ford, Anthony P.
    Tershakovec, Andrew M.
    Wu, Wen-Chi
    Brindle, Kayleigh
    Thompson, Rachel
    Thackray-Nocera, Susannah
    Wright, Caroline
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54 (01)
  • [35] Safety of the muscarinic receptor-antagonist (R,R)-penehyclidine fumarate in healthy subjects: A phase 1 randomized, double-blind, single-dose escalation study
    Fu, Chengxiao
    Zhang, Xingfei
    Pei, Qi
    Guo, Chengxian
    Yang, Xiaoyan
    Yang, Shuang
    Huang, Jie
    Yang, Guoping
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (03) : 155 - 165
  • [36] A randomised, double-blind, phase I study to compare the pharmacokinetics, safety, tolerability, and immunogenicity of HLX15 and daratumumab in healthy male participants
    Su, Y-W.
    Wang, X.
    Wang, Y-H.
    Xu, Y.
    Zhang, Q.
    Gao, X.
    Liu, Y.
    Bai, W.
    Sun, C.
    Zhou, L.
    Yu, H.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S1428 - S1429
  • [37] Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men
    Friedrich, Christian
    Singh, Dave
    Francke, Klaus
    Klein, Stefan
    Hetzel, Terence
    Zolk, Oliver
    Gashaw, Isabella
    Scheerans, Christian
    Morice, Alyn
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (08) : 2004 - 2018
  • [38] A randomised, double-blind, placebo-controlled, first-in-human phase I study to characterise the safety, pharmacokinetics and immunogenicity of 9MW1411 in healthy Chinese subjects
    Yang, Haijing
    Wang, Peipei
    Li, Xin
    Wei, Qiong
    Yu, Jicheng
    Wu, Xiaojie
    Huang, Ying
    Li, Ruowan
    Du, Weijuan
    Zeng, Shaoqing
    Wu, Hailan
    Wang, Shuhai
    Zhang, Jing
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (02)
  • [39] Phase I, double-blind, placebo-controlled study in healthy male subjects to investigate the safety, tolerability, and pharmacokinetics of DA-8159
    Padma-Nathan, H
    Pacik, JS
    Ahn, BO
    Kang, KK
    Bahng, MY
    Kim, WB
    JOURNAL OF UROLOGY, 2004, 171 (04): : 234 - 234
  • [40] A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects
    Leubitz, Andi
    Vanhoutte, Frederic
    Hu, Ming-yi
    Porter, Kaela
    Gordon, Efrat
    Tencer, Kathleen
    Campbell, Kathleen
    Banks, Kate
    Haverty, Tom
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (08): : 859 - 869
12345